MX374468B - Composicion farmaceutica acuosa semisolida que contiene tapentadol. - Google Patents

Composicion farmaceutica acuosa semisolida que contiene tapentadol.

Info

Publication number
MX374468B
MX374468B MX2016016703A MX2016016703A MX374468B MX 374468 B MX374468 B MX 374468B MX 2016016703 A MX2016016703 A MX 2016016703A MX 2016016703 A MX2016016703 A MX 2016016703A MX 374468 B MX374468 B MX 374468B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
composition containing
semi
aqueous pharmaceutical
solid aqueous
Prior art date
Application number
MX2016016703A
Other languages
English (en)
Spanish (es)
Inventor
Eva Wulsten
Marc Schiller
Roger Carolus Augusta Embrechts
Sabine Karine Katrien Inghelbrecht
Ulrich Feil
Ulrich Reinhold
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX374468B publication Critical patent/MX374468B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2016016703A 2011-03-04 2012-03-02 Composicion farmaceutica acuosa semisolida que contiene tapentadol. MX374468B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
EP11003603 2011-05-03
PCT/EP2012/000906 WO2012119729A1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol

Publications (1)

Publication Number Publication Date
MX374468B true MX374468B (es) 2025-03-06

Family

ID=44652117

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016016703A MX374468B (es) 2011-03-04 2012-03-02 Composicion farmaceutica acuosa semisolida que contiene tapentadol.
MX2013010100A MX344473B (es) 2011-03-04 2012-03-02 Composicion farmaceutica acuosa semisolida que contiene tapentadol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013010100A MX344473B (es) 2011-03-04 2012-03-02 Composicion farmaceutica acuosa semisolida que contiene tapentadol.

Country Status (24)

Country Link
US (3) US9446008B2 (OSRAM)
EP (3) EP2680834B1 (OSRAM)
JP (3) JP6027549B2 (OSRAM)
KR (2) KR101911362B1 (OSRAM)
CN (1) CN103501774A (OSRAM)
AU (2) AU2012224954C1 (OSRAM)
BR (1) BR112013022556A8 (OSRAM)
CA (1) CA2828637C (OSRAM)
CY (1) CY1119725T1 (OSRAM)
DK (1) DK2680834T3 (OSRAM)
EA (2) EA025194B1 (OSRAM)
ES (2) ES2654407T3 (OSRAM)
HR (1) HRP20171836T1 (OSRAM)
HU (1) HUE037491T2 (OSRAM)
IL (2) IL227826B (OSRAM)
LT (1) LT2680834T (OSRAM)
MX (2) MX374468B (OSRAM)
NO (1) NO2680834T3 (OSRAM)
PL (1) PL2680834T3 (OSRAM)
PT (2) PT2680834T (OSRAM)
RS (1) RS56692B1 (OSRAM)
SI (1) SI2680834T1 (OSRAM)
WO (1) WO2012119729A1 (OSRAM)
ZA (1) ZA201306480B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3287123T1 (sl) 2011-03-04 2020-07-31 Gruenenthal Gmbh Vodna farmacevtska formulacija tapentadola za peroralno uporabo
KR101911362B1 (ko) 2011-03-04 2018-10-25 그뤼넨탈 게엠베하 타펜타돌을 함유하는 반고체 수성 약제학적 조성물
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
EP3027214A1 (en) * 2013-08-02 2016-06-08 ratiopharm GmbH Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
PT3479823T (pt) 2015-03-27 2020-09-29 Gruenenthal Gmbh Formulação estável para administração parentérica de tapentadol
EP3515412B1 (en) * 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
EP3826631A1 (en) * 2018-07-24 2021-06-02 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical emulsion of an anticholinergic compound
US12447119B2 (en) 2019-03-18 2025-10-21 Sunstar Americas, Inc. Oral care composition

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
PL223471B1 (pl) 2002-03-15 2016-10-31 Cypress Bioscience Inc Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
BR0314269A (pt) 2002-09-13 2005-07-26 Cydex Inc Cápsulas contendo composições aquosas de recheio estabilizadas com ciclodextrina derivatizada
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
US20060111382A1 (en) 2004-05-17 2006-05-25 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
PT1612203E (pt) 2004-06-28 2007-08-20 Gruenenthal Gmbh ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol''
CA2572352A1 (en) 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
JP2008539269A (ja) 2005-04-28 2008-11-13 セラクエスト バイオサイエンシズ エルエルシー 疼痛を治療するための方法および組成物
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
WO2007127158A2 (en) * 2006-04-25 2007-11-08 Croda, Inc Modification of percutaneous absorption of topically active materials
SI2012763T1 (sl) 2006-04-28 2011-06-30 Gruenenthal Gmbh Farmacevtska kombinacija, ki obsega 3-(3-dimetilamino-1-etil-2-metil- propil)-fenol in NSAID
DE602007011913D1 (de) 2006-04-28 2011-02-24 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
MX2009000911A (es) 2006-07-24 2009-02-04 Janssen Pharmaceutica Nv Preparacion de (2r,3r)-3-(3-metoxifenil)-n,n,2-trimetilpentanamina .
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
MX360289B (es) 2007-11-23 2018-10-29 Gruenenthal Gmbh Composiciones de tapentadol.
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
JP6216489B2 (ja) 2008-10-30 2017-10-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 新規の、効力のあるタペンタドール剤形
US20100227921A1 (en) 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
WO2011120084A1 (en) * 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
KR101911362B1 (ko) 2011-03-04 2018-10-25 그뤼넨탈 게엠베하 타펜타돌을 함유하는 반고체 수성 약제학적 조성물

Also Published As

Publication number Publication date
BR112013022556A8 (pt) 2018-01-16
PT3766489T (pt) 2022-04-07
EP3766489A1 (en) 2021-01-20
CN103501774A (zh) 2014-01-08
JP2014506900A (ja) 2014-03-20
AU2017200040B2 (en) 2018-09-06
EP3766489B1 (en) 2022-03-16
AU2012224954C1 (en) 2017-04-06
EP2680834A1 (en) 2014-01-08
HRP20171836T1 (hr) 2017-12-29
WO2012119729A1 (en) 2012-09-13
JP2018065839A (ja) 2018-04-26
EA201600442A1 (ru) 2017-02-28
EP3290029B1 (en) 2020-09-02
JP6259042B2 (ja) 2018-01-10
JP6027549B2 (ja) 2016-11-16
HUE037491T2 (hu) 2018-09-28
IL227826A0 (en) 2013-09-30
EP2680834B1 (en) 2017-10-18
US20180133174A1 (en) 2018-05-17
MX344473B (es) 2016-12-16
EA033171B1 (ru) 2019-09-30
LT2680834T (lt) 2018-01-10
ZA201306480B (en) 2014-05-28
JP6670283B2 (ja) 2020-03-18
AU2012224954A1 (en) 2013-09-19
CA2828637C (en) 2019-06-11
PL2680834T3 (pl) 2018-03-30
BR112013022556A2 (pt) 2016-12-06
EA025194B1 (ru) 2016-11-30
MX2013010100A (es) 2013-10-01
US20160346229A1 (en) 2016-12-01
KR20140013020A (ko) 2014-02-04
IL258357A (en) 2018-05-31
ES2910085T3 (es) 2022-05-11
NO2680834T3 (OSRAM) 2018-03-17
SI2680834T1 (en) 2018-01-31
KR20180116463A (ko) 2018-10-24
CY1119725T1 (el) 2018-06-27
IL227826B (en) 2018-04-30
EP3290029A1 (en) 2018-03-07
KR101911362B1 (ko) 2018-10-25
ES2654407T3 (es) 2018-02-13
AU2012224954B2 (en) 2016-10-20
KR102039320B1 (ko) 2019-11-01
CA2828637A1 (en) 2012-09-13
AU2017200040A1 (en) 2017-02-02
PT2680834T (pt) 2018-01-25
US9446008B2 (en) 2016-09-20
US20120225950A1 (en) 2012-09-06
RS56692B1 (sr) 2018-03-30
DK2680834T3 (en) 2017-12-04
JP2017039756A (ja) 2017-02-23
EA201300988A1 (ru) 2014-06-30

Similar Documents

Publication Publication Date Title
MX374468B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
JOP20180102B1 (ar) مركب صيدلاني
CR20130406A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
CR20150120A (es) Nuevos derivados bicíclicos
EA201692443A1 (ru) Водная фармацевтическая композиция тапентадола для перорального введения
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
EA201590296A1 (ru) Дейтерированный ибрутиниб
ECSP11011391A (es) Métodos y productos intermedios para preparar agentes farmacéuticos
BR112015000329A2 (pt) formulações de diclofenac
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
ECSP15010550A (es) Preparación farmacéutica sólida que contiene levotiroxina
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
CO7010828A2 (es) Preparación farmacéutica que comprende ߖciclodextrina sustituida
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
EA201491300A1 (ru) Композиция для назального применения с улучшенной стабильностью
BR112015014078A2 (pt) composição farmacêutica oftalmológica tópica que contém regorefenib
CO6761388A2 (es) Composiciones pharmaceuticas que comprenden alisporivir
EP2851075A4 (en) PREPARATION WITH 6,7-UNSATED 7-CARBAMOYLMORPHINANE DERIVATIVE
BR112013029778A2 (pt) composição farmacêutica que compreende fexofenadina
PT2594266E (pt) Composições farmacêuticas sólidas que contêm sais de ibuprofeno
CO6801771A2 (es) Composición oral que comprende sodio divalproexy proceso para preparar la misma
GT201200066A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112013025766A2 (pt) composições farmacêuticas de liberação modificada de desvenlafaxina